These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38519028)

  • 1. Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
    Kamrul-Hasan ABM; Mondal S; Nagendra L; Yadav A; Aalpona FTZ; Dutta D
    Endocr Pract; 2024 May; 30(5):431-440. PubMed ID: 38519028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials.
    Grando Alves G; Cunha L; Henkes Machado R; Lins de Menezes V
    Diabetes Obes Metab; 2024 Jul; 26(7):2652-2661. PubMed ID: 38602411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
    Ramos EL; Dayan CM; Chatenoud L; Sumnik Z; Simmons KM; Szypowska A; Gitelman SE; Knecht LA; Niemoeller E; Tian W; Herold KC;
    N Engl J Med; 2023 Dec; 389(23):2151-2161. PubMed ID: 37861217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis.
    Nourelden AZ; Elshanbary AA; El-Sherif L; Benmelouka AY; Rohim HI; Helmy SK; Sayed MK; Ismail A; Ali AS; Ragab KM; Zaazouee MS
    Endocr Metab Immune Disord Drug Targets; 2021; 21(10):1895-1904. PubMed ID: 33302842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
    Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
    Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
    Herold KC; Gitelman SE; Willi SM; Gottlieb PA; Waldron-Lynch F; Devine L; Sherr J; Rosenthal SM; Adi S; Jalaludin MY; Michels AW; Dziura J; Bluestone JA
    Diabetologia; 2013 Feb; 56(2):391-400. PubMed ID: 23086558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
    Herold KC; Gitelman SE; Ehlers MR; Gottlieb PA; Greenbaum CJ; Hagopian W; Boyle KD; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; McNamara J; Bluestone JA;
    Diabetes; 2013 Nov; 62(11):3766-74. PubMed ID: 23835333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.
    Herold KC; Gitelman SE; Gottlieb PA; Knecht LA; Raymond R; Ramos EL
    Diabetes Care; 2023 Oct; 46(10):1848-1856. PubMed ID: 37607392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
    N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
    Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
    Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
    Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
    Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD3 monoclonal antibodies in treatment of type 1 diabetes: a systematic review and meta-analysis.
    Liu Y; Li W; Chen Y; Wang X
    Endocrine; 2024 Feb; 83(2):322-329. PubMed ID: 37658243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of teplizumab for treatment of type 1 diabetes: A meta-analysis of randomized controlled trials.
    Heidari E; Shafiee A; Noorian S; Rafiei MA; Abbasi M; Amini MJ; Safari O; Aghamahdi F; Bakhtiyari M
    Diabetes Metab Res Rev; 2024 May; 40(4):e3806. PubMed ID: 38757421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teplizumab for treatment of type 1 diabetes mellitus.
    Skelley JW; Elmore LK; Kyle JA
    Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
    Hagopian W; Ferry RJ; Sherry N; Carlin D; Bonvini E; Johnson S; Stein KE; Koenig S; Daifotis AG; Herold KC; Ludvigsson J;
    Diabetes; 2013 Nov; 62(11):3901-8. PubMed ID: 23801579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
    Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
    Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of Metabolic Measures to Predict T1D vs Detect a Preventive Treatment Effect in High-Risk Individuals.
    Sims EK; Cuthbertson D; Jacobsen L; Ismail HM; Nathan BM; Herold KC; Redondo MJ; Sosenko J
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2116-2123. PubMed ID: 38267821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.
    Sims EK; Bundy BN; Stier K; Serti E; Lim N; Long SA; Geyer SM; Moran A; Greenbaum CJ; Evans-Molina C; Herold KC;
    Sci Transl Med; 2021 Mar; 13(583):. PubMed ID: 33658358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
    Fanaropoulou NM; Tsatsani GC; Koufakis T; Kotsa K
    Expert Rev Clin Immunol; 2024 Feb; 20(2):185-196. PubMed ID: 37937833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.